Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22796294 | 0.82 | CD274 (0.46) | PDCD1CD274SMN1; SMN2PLD1ESD | |
| SCHEMBL908008 | 0.80 | KDM4E (0.38) | PDCD1CD274SMN1; SMN2PLD1ESD | |
| SCHEMBL10855110 | 0.78 | ESD (0.53) | PDCD1CD274POLBPLD1ESD | |
| SCHEMBL7721905 | 0.76 | L3MBTL1 (0.40) | POLBSMN1; SMN2ALDH1A1HPGDMAPT | |
| SCHEMBL19866263 | 0.74 | SMN1; SMN2 (0.56) | HSD11B1PDCD1CD274POLBSMN1; SMN2 | |
| SCHEMBL11059805 | 0.71 | MEN1 (0.41) | POLBSMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL908132 | 0.69 | HSD11B1 (0.40) | HSD11B1ROCK1MAP4K4PIM1PRKACA | |
| SCHEMBL19866242 | 0.69 | SMN1; SMN2 (0.40) | PDCD1CD274SMN1; SMN2ESDALDH1A1 | |
| SCHEMBL907974 | 0.67 | PRKCZ (0.41) | ABL1 | |
| SCHEMBL7719321 | 0.67 | PRKCZ (0.40) | SMN1; SMN2ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-4622401-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0070376-A1 | Heterocyclic substituted-amino-pyrazolines | AMERICAN CYANAMID COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | DAO, DDO, MAOA | HSD11B1 1745/4885ROCK1 3441/4885MAP4K4 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.